HTGF, Bayern Kapital exit ChromoTek to trade

Following the acquisition, both companies plan to continue to work on single-cell analysis, super resolution imaging, and multiplex assays, according to a statement.

HTGF has now made 10 exits since May 2020, according to Unquote Data.

Previous funding
Bayern Kapital and HTGF invested €400,000 in ChronoTek in July 2010; the fresh capital was intended to support the company's continued research and development.

Company
ChromoTek develops alpaca single-domain antibodies known as nanobodies, for use in biotechnology research. The company has developed tools for immunoprecipitation called Nano-Traps.

ChromoTek was founded in 2008 as a spinout from Munich's Ludwig Maximilian University. It has 18 employees, according to LinkedIn.

People
High-Tech Gründerfonds – Bernd Goergen (partner).
ChromoTek – Marion Jung (CEO).
Proteintech – Jason Li (CEO).

Advisers
Vendor – Lupp + Partner (legal); Binder Associates (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• Trade sale
• Germany
• High-Tech Gründerfonds